Blog
RSS FeedPosted by Michael Wonder on 09 Mar 2025
Expanded reimbursement for Rinvoq enhances atopic dermatitis treatment options
7 March 2025 - Korean patients with moderate to severe atopic dermatitis now have greater flexibility in treatment as reimbursement ...
Posted by Michael Wonder on 04 Mar 2025
Roche Korea’s multiple sclerosis drug scores reimbursement
4 March 2025 - Roche Korea said its multiple sclerosis treatment, Ocrevus (ocrelizumab), started receiving reimbursement from last Saturday. ...
Posted by Michael Wonder on 03 Mar 2025
Amyloid cardiomyopathy drug Vyndamax to get health insurance from March
28 February 2025 - Vyndamax (tafamidis), a transthyretin amyloid cardiomyopathy medicine that has experienced difficulties getting on the health insurance ...
Posted by Michael Wonder on 23 Feb 2025
HIRA to remove 17 medicines from group 2 anti-cancer list, update reimbursement criteria
21 February 2025 - Korea's HIRA said it has decided to remove 17 medicines from the list of group 2 ...
Posted by Michael Wonder on 20 Feb 2025
Korea to implement new drug pricing policy that rewards innovation
20 February 2025 - The Ministry of Health and Welfare on Thursday announced a significant policy change in pharmaceutical pricing ...
Posted by Michael Wonder on 13 Feb 2025
Keytruda gets expanded coverage for 11 indications at cancer disease panel
13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun. ...
Posted by Michael Wonder on 11 Feb 2025
Gilead’s breast cancer treatment Trodelvy passes drug reimbursement panel
7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health ...
Posted by Michael Wonder on 01 Feb 2025
Boehringer Ingelheim’s Jardiance gets expanded coverage for HFpEF patients
31 January 2025 - Boehringer Ingelheim Korea said that Jardiance (empagliflozin) 10 mg tablet, its sodium-glucose co-transporter-2 inhibitor, received expanded ...
Posted by Michael Wonder on 21 Jan 2025
Immunotherapy Qarziba to be reimbursed for high-risk neuroblastoma patients starting next month
28 November 2024 - The treatment landscape for neuroblastoma, the most common cancer in children outside of blood and brain ...
Posted by Michael Wonder on 20 Jan 2025
Handok's AML treatment Vyxeos receives insurance coverage in Korea
2 December 2024 - Handok said Monday that its acute myeloid leukaemia treatment, Vyxeos liposomal injection (cytosine arabinoside and daunorubicin ...
Posted by Michael Wonder on 08 Jan 2025
Korea's only RET inhibitor, Retevmo, seeks insurance coverage again
6 January 2025 - Lilly Korea is again pursuing reimbursement for Retevmo (selpercatinib), the only RET inhibitor in Korea. ...
Posted by Michael Wonder on 12 Dec 2024
Merck's Tepmetko, GSK-Janssen's Vocabria+Rekambys combo move closer to reimbursement in Korea
6 December 2024 - Merck's MET inhibitor Tepmetko (tepotinib) has been recognized by the national health insurance reviewer as eligible ...
Posted by Michael Wonder on 02 Dec 2024
Gilead’s Trodelvy awaits re-deliberation for reimbursement in Korea following patient petitions, price cut proposal
25 November 2024 - The triple negative breast cancer treatment Trodelvy (sacituzumab govitecan), which drew 100,000 petitions from patients, will ...
Posted by Michael Wonder on 02 Nov 2024
Handok's rare blood disorder treatment Empaveli wins insurance coverage
1 November 2024 - Starting today, Handok's Empaveli (pegcetacoplan), a treatment for paroxysmal nocturnal haemoglobinuria, will be covered by Korean ...
Posted by Michael Wonder on 21 Oct 2024
Drug price negotiations for obstructive hypertrophic cardiomyopathy drug Camzyos stall, delaying reimbursement
21 October 2024 - Urgent attention is on the drug price negotiations for the obstructive hypertrophic cardiomyopathy (oHCM) treatment Camzyos ...